# Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma

> **NCT02050919** · PHASE2 · COMPLETED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 20 (actual)

## Conditions studied

- Pleomorphic Rhabdomyosarcoma
- Stage IIB Adult Soft Tissue Sarcoma AJCC v7
- Stage III Adult Soft Tissue Sarcoma AJCC v7
- Stage IV Adult Soft Tissue Sarcoma AJCC v7

## Interventions

- **DRUG:** Epirubicin Hydrochloride
- **RADIATION:** External Beam Radiation Therapy
- **DRUG:** Ifosfamide
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Sorafenib Tosylate
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT02050919
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-03
- **Primary completion:** 2018-05-07
- **Final completion:** 2020-12-31
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-03-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02050919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02050919, "Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02050919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*